|
Alzheimer's Disease in the News
Columbia researchers restore memory lost in mice with Alzheimer's
Boosting a newly discovered enzyme helps mice regain normal cognitive function
NEW YORK August 24, 2006 -- Researchers at Columbia University Medical Center have successfully restored normal memory and synaptic function in mice suffering from
Alzheimer's disease. The study was published today on the website of the journal Cell.
Scientists at Columbia's Taub Institute for Research on Alzheimer's Disease and the Aging Brain have identified an enzyme that is required for normal cognition
but that is impaired in a mouse model of Alzheimer's. They discovered that mice regained the ability to form new memories when the enzyme's function was elevated.
The research suggests that boosting the function of this enzyme, known as ubiquitin C-terminal hydrolase L1 (Uch-L1), may provide a promising strategy for battling
Alzheimer's disease, and perhaps reversing its effects.
In the new study, the Columbia researchers discovered that the enzyme Uch-L1 is part of a molecular network that controls a memory molecule called CREB, which is
inhibited by amyloid beta proteins in people with Alzheimer's. By increasing Uch-L1 levels in mice that had Alzheimer's, they were able to improve the animals' ability to create new memories.
"Because the amyloid beta proteins that cause Alzheimer's may play a normal, important physiological role in the body, we can't destroy them as a
therapy," explained Ottavio Arancio, M.D., Ph.D., Assistant Professor of Pathology at Columbia University Medical Center and co-principal investigator of the study with Michael Shelanski, MD, Ph.D.,
Chairman of the Department of Pathology at the Columbia University College of Physicians and Surgeons. "What makes this newly discovered enzyme exciting as a potentially effective therapy is that it
restores memory without destroying amyloid beta proteins."
The researchers tested the memory of the mice by putting them in a cage where they were exposed to a mild stimulus when they touched the cage floor. Mice with normal
memory remain still the second time they're placed in the cage, as they recognize the place where they were initially exposed to the stimulus. But mice with Alzheimer's-like changes do not
remember the place, and continue moving within the cage. When the Alzheimer's mice were treated with Uch-L1, they acted like normal mice, and remained still.
"While this discovery is very promising, its proven effectiveness is limited to animal models and it will take some time before it could lead to therapies in
humans," said Dr. Shelanski. "We continue to work towards that crucial goal." The work was supported by the National Institutes of Neurological Disease and Stroke and the Alzheimer's
Center Program of the National Institute of Aging.
No magic bullet for Alzheimer's Disease - Gather.com
BETHESDA, Md. — The scene was a kind of science court. On trial was the question “Can anything — running on a treadmill, eating more spinach, learning Arabic — prevent Alzheimer’s disease or delay ...
Rheumatoid Arthritis Signaling Protein GM-CSF Reverses Alzheimer's Disease In Mouse ... - Medical News Today
A signaling protein released during rheumatoid arthritis dramatically reduced Alzheimer's disease pathology and reversed the memory impairment of mice bred to develop symptoms of the neurodegenerative disease ...
Nobel winner's new discovery may offer target for Alzheimer drugs - Denver Post
... Alzheimer's disease whipsaws between encouraging and disheartening, a new discovery by an 84-year-old scientist has illuminated a new direction. The scientist, Dr. Paul Greengard ... to make beta amyloid,
Cell publishes on the critical role of metals in Alzheimer's Disease - Phramalive.com
... Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried ...
Diabetes mellitus (Type 2) linked to Alzheimer's disease - Food Consumer
People with insulin resistance or type 2 diabetes mellitus may be at higher risk for developing plaques in the brain that are linked with Alzheimer's disease, a new study published in the August 25, 2010, issue of ...
Fisher Scientists Discover Protein that Fuels Alzheimer's Disease, Promising New ... - Earthtimes
... Protein is a Therapeutic Target for Alzheimer's Disease" in Nature online. Â Drs. Gen He (lead author) and Paul Greengard ... Gleevec, which Fisher scientists previously showed could lower beta-amyloid levels in ...
Addex drug-candidate effective in Alzheimer's disease model - msnbc.com
Alzheimer's disease is a progressive brain disease affecting up to 5.3 million Americans and the seventh-leading cause of death in the United States. It destroys brain cells causing memory loss and problems with ...
Insulin Resistance, Type 2 Diabetes Linked To Plaques Associated With Alzheimer's Disease - Redorbit.com
... medical journal of the American Academy of Neurology. Insulin resistance, or the stage before diabetes, happens when insulin, a hormone in the body, becomes less effective in lowering blood sugar. "Type 2 ...
Alzheimer's disease researchers check egos at the door - St. Petersburg Times
In 2003, a group of scientists and executives from the National Institutes of Health, the Food and Drug Administration, the drug and medical-imaging industries, universities and nonprofit groups joined in a ...
|
|
